After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in patients with non-alcoholic steatohepatitis (NASH). Galmed said the data "strongly support" a Phase III trial of the synthetic conjugate of cholic acid and

Read the full 499 word article

User Sign In